The Latest Breaking News from Obesity

Weight loss jabs could keep people in work, according to a study of 700 NHS patients

A study of more than 10,000 12-year-olds found the earlier children acquired smartphones, the greater the risk of obesity, poor sleep, and depression

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.

The global health body issued its first guidance on the use of blockbuster weight loss drugs.

WHO urges countries to make drugs such as Mounjaro more accessible to people and asks drugs companies to lower prices

Soybean oil is commonly found in processed foods and has been linked to obesity

Excess weight, especially around the waist, leads to fatty material building up in the arteries and major organs

Preteens who own smartphones are likelier to have depression, obesity and insufficient sleep than their peers.

Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The results close the door, for now, on hopes that a treatment for diabetes and obesity might also help protect the brain.